MedTrace Logo

Identification of Non-responders to Levothyroxine Therapy

NCT03627611 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2021-03-17

No results posted yet for this study

Summary

The purpose of this study is to assess differential effects of T4 and T3 on cell and tissue level

Conditions

Interventions

DRUG

Levothyroxin

3 months

DRUG

Liothyronine

3 months

Sponsors & Collaborators

  • Hormonlaboratoriet

    collaborator UNKNOWN

  • Spesialistsenteret Pilestredet Park

    collaborator UNKNOWN

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Erik Fink Eriksen, Professor · Department of Endocrinology, Morbid Obesity and Preventive Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-14
Primary Completion
2020-06-22
Completion
2020-06-22

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03627611 on ClinicalTrials.gov